Zobrazeno 1 - 10
of 2 715
pro vyhledávání: ''
Autor:
Seong Hyun, Jeong, Seok Jin, Kim, Dok Hyun, Yoon, Yong, Park, Hye Jin, Kang, Youngil, Koh, Gyeong-Won, Lee, Won-Sik, Lee, Deok-Hwan, Yang, Young Rok, Do, Min Kyoung, Kim, Kwai Han, Yoo, Yoon Seok, Choi, Hwan Jung, Yun, Jun Ho, Yi, Jae-Cheol, Jo, Hyeon-Seok, Eom, Jae-Yong, Kwak, Ho-Jin, Shin, Byeong Bae, Park, Shin Young, Hyun, Seong Yoon, Yi, Ji-Hyun, Kwon, Sung Yong, Oh, Hyo Jung, Kim, Byeong Seok, Sohn, Jong Ho, Won, Se-Hyung, Kim, Ho-Sup, Lee, Cheolwon, Suh, Won Seog, Kim
Publikováno v:
Cancer Research and Treatment. 54:1268-1277
PurposeFebrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). Mate
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:e938-e946
One key clinical challenge remains in how to sequence treatments in follicular lymphoma (FL). The chemoimmunotherapy rituximab cyclophosphamide, doxorubicin, vincristine (Oncovin), and prednisone (R-CHOP) has been a standard treatment option for two
Autor:
Maja Bech Juul, Jelena Jelicic, Pavithra Laxsen Anru, Henriette Engberg, Pernille Hammershøj Jensen, Helene Bjørg Kristensen, Joachim Baech, Michael Roost Clausen, Anne Ortved Gang, Lars Munksgaard, Tarec Christoffer El-Galaly, Henrik Frederiksen, Thomas Stauffer Larsen
Publikováno v:
Juul, M B, Jelicic, J, Anru, P L, Engberg, H, Hammershøj Jensen, P, Kristensen, H B, Baech, J, Clausen, M R, Gang, A O, Munksgaard, L, El-Galaly, T C, Frederiksen, H & Stauffer Larsen, T 2022, ' Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma : a Danish population-based cohort study ', Leukemia and Lymphoma, vol. 63, no. 9, pp. 2074-2083 . https://doi.org/10.1080/10428194.2022.2064982
Diffuse large B-cell lymphoma is an aggressive disease occurring primarily in elderly patients. Despite high curative rates with doxorubicin-containing treatment, some elderly patients receive less intensive treatments, mainly due to advanced age, co
Autor:
María Elena Cabrera, Camila Peña, Pilar Leon, Vivianne Lois, Hernán Rojas, Valeska Vega, Alvaro Pizarro, Susana Calderon, Christine Rojas, Augusto Aspillaga, M. Luisa Gonzalez, Marvila Intriago, Bernardita Rojas, Cecilia Hales, Jacqueline Oliva, Mónica Romero, Marisa Capurro, Jorge J. Castillo
Publikováno v:
JCO Global Oncology.
PURPOSE Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype. The purpose of this study was to evaluate the clinical features, prognostic factors, and results of DLBCL that was treated in the cancer centers of the public health s
Autor:
Ursa Brown-Glaberman, Hannah M. Linden, Lynn Symonds, Jennifer M. Specht, Eve T. Rodler, Isaac C. Jenkins, Xiaoyu Chai, Georgiana K. Ellis, Pavani Chalasani, Jinny Riedel, Brenda F. Kurland, Julie Gralow, Alison Stopeck, Qian Wu, Vijayakrishna V K Gadi
Publikováno v:
Clin Breast Cancer
INTRODUCTION Neoadjuvant chemotherapy is standard treatment for locally advanced (LABC) or inflammatory breast cancer (IBC). We hypothesized adding sunitinib, a tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity, to an anthracycli
Autor:
Lucile Bussot, Simon Chevalier, Caroline Algrin, Anouk Emadali, Laurence David-Boudet, Christine Lefebvre, Cyril Fournier, Laurent Martin, Claire Vettier, O. Casasnovas, Remy Gressin, Caroline Chapusot, Mary Callanan, Edwige Col, Thierry Bonnefoix, Marie-Christine Jacob, Anne McLeer, Antonin Bouroumeau, Tatiana Raskovalova, Hervé Sartelet
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 7, Iss 6, Pp 604-615 (2021)
The Journal of Pathology: Clinical Research
The Journal of Pathology: Clinical Research
Diffuse large B‐cell lymphoma (DLBCL) is a clinically heterogeneous entity, in which the first‐line treatment currently consists of an immuno‐chemotherapy regimen (R‐CHOP). However, around 30% of patients will not respond or will relapse. Ove
Autor:
Nancy Chan, Jiuping Ji, Antoinette R. Tan, Janice M. Mehnert, Alice P. Chen, Jan H. Beumer, Mansi Shah, Joseph Aisner, Murugesan Gounder, Jyoti Malhotra, Rebecca A. Moss, Yong Lin, Brian F. Kiesel, Hongxia Lin, Mark N. Stein, Michael P. Kane
Publikováno v:
Cancer Chemother Pharmacol
Purpose Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus
Autor:
Jean El Cheikh, Iman Abou Dalle, Jeries Kort, Farouk Al Chami, Maya Charafeddine, Haidar El Darsa, Rola El Sayed, Ali Ibrahim, Ali Bazarbachi
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:711-719
Background Intensified immunochemotherapy with rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP) improves outcomes in younger adults with diffuse large B-cell lymphomas (DLBCL) compared with R-CHOP. Due to vinde
Autor:
Wenqi Jiang, Li-Qin Ping, Qingqing Cai, Bing Bai, Xiaoxiao Wang, Jibin Li, Qixiang Rong, Jia-Ying Mao, Yan-Xia He, Haixia He, Cheng Huang, Yan Gao, Zhi Ming Li, He Huang, Huiqiang Huang
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 21, Pp 7650-7664 (2021)
Cancer Medicine, Vol 10, Iss 21, Pp 7650-7664 (2021)
Purpose Some studies have indicated that using 500 mg/m2 rituximab combined with CHOP‐14 may be beneficial for elderly men but not women with diffuse large B‐cell lymphoma (DLBCL). The purpose of this study was to investigate the potential benefi
Autor:
Ángela Ibañez-García, Alberto Marín-Sánchez, Irene Gómez-Catalán, Mari Carmen Montoya-Morcillo, Francisco Hernández-Fernández, Gonzalo Martínez-Fernández, Jesús Lorenzo Algarra-Algarra, Juan Ramón Romero-Macías
Publikováno v:
Experimental Hematology. :49-57
The hyper-CVAD/methotrexate-cytarabine (H-CVAD/ MTX-AraC) chemotherapy protocol has been one of the standard treatments for hematological malignancies, such as mantle cell lymphoma (MCL), Burkitt lymphoma (BL), and B-cell and T-cell acute lymphoblast